Since a functional and physical association between ERBB2 family members and the RANK receptor has been shown, clinical trials of combinatorial administration of immune checkpoint inhibitors and anti-RANKL agents in breast cancer, especially in RANK-expressing ERBB2-positive patients, are needed. Here, ERBB2 is linked to breast cancer.